HighQC™ Human IPSC-Derived Cardiac Cells: I-HCm

Human iPSC-Derived Cardiac Cells contain i-HCm make a powerful in vitro platform to study cardiac physiology and disease, and to assess therapeutic compound efficacy, safety and toxicity1-3. These iPSC-Derived Cardiac Cells are differentiated from integration-free Human Induced Pluripotent Stem Cells (HiPSC), which are fully validated for pluripotency and cultured under feeder-free conditions before cryopreservation. Through a robust serum-free, chemically defined protocol, high yields of fully functional Cardiac Cells are obtained and cryopreserved. Of note, the i-HCm and other cardiac cell populations are not purified through genetic selection, and thus there is no risk of genotoxic stress due to molecular manipulation. Furthermore, cellular preparations include accessory cellular populations resident in the human heart, which are crucial for correct cardiomyocyte physiology2, 4. Characterization Post-thawing viability and plating efficiencies of the cells are typically higher than 50%. After plating at the recommended density, the cells will show spontaneous synchronized beating, and will express typical cardiomyocyte markers, such as the contractile proteins cardiac troponin T (cTNT) and sarcomeric alpha actinin (SaAct). The cardiomyocyte content of our preparations is determined by flow cytometry analysis and quantification of cardiac troponin T positive cells. These iPSC-Derived Cardiac Cells are also tested to ensure the absence of microorganism contaminants. Applications Independent assays: From electrophysiology and multi-electrode array analysis to high content microscopy and viability screens. Cardiac Disease modeling: To date, interesting phenotypes of several genetic-based cardiomyopathies have been successfully replicated in a dish through the use of patient-specific i-HCm. Examples include Familial Hypertrophic, Dilated, and Arrhythmogenic Right Ventricular Cardiomyopathies1-3. Cardiac safety and toxicity: Cardiac toxicity is an important contributor for the failure of therapeutic agents in late stages of clinical trials, as well as for the removal of approved drugs from the market. Through the CiPA initiative, which brings together researchers from institutions such as the FDA, academic institutions and pharmaceutical companies, i-HCm are being evaluated as an integral tool for the safety assessment of developing drugs5,6.